Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CRL 
Charles River Laboratories (CRL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: CRL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $156.14
1 Year Target Price $156.14
| 4 | Strong Buy |
| 0 | Buy |
| 14 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.63% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.81B USD | Price to earnings Ratio - | 1Y Target Price 156.14 |
Price to earnings Ratio - | 1Y Target Price 156.14 | ||
Volume (30-day avg) 19 | Beta 1.48 | 52 Weeks Range 91.86 - 254.15 | Updated Date 07/10/2025 |
52 Weeks Range 91.86 - 254.15 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.6 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -0.49% | Operating Margin (TTM) 13.62% |
Management Effectiveness
Return on Assets (TTM) 4.27% | Return on Equity (TTM) -0.67% |
Valuation
Trailing PE - | Forward PE 16.64 | Enterprise Value 10564433736 | Price to Sales(TTM) 1.94 |
Enterprise Value 10564433736 | Price to Sales(TTM) 1.94 | ||
Enterprise Value to Revenue 2.63 | Enterprise Value to EBITDA 19.35 | Shares Outstanding 49115700 | Shares Floating 48532708 |
Shares Outstanding 49115700 | Shares Floating 48532708 | ||
Percent Insiders 1.01 | Percent Institutions 111.1 |
Upturn AI SWOT
Charles River Laboratories
Company Overview
History and Background
Charles River Laboratories was founded in 1947 by Henry Foster as a small laboratory rabbitry. Over the decades, it expanded through acquisitions and organic growth to become a leading provider of research models, preclinical and clinical laboratory services, and manufacturing support to the pharmaceutical, biotechnology, and agricultural industries.
Core Business Areas
- Research Models and Services (RMS): Provides research models (laboratory animals), genetically engineered models and services (GEMS), and related services like veterinary care and husbandry.
- Discovery and Safety Assessment (DSA): Offers preclinical research services including drug discovery, toxicology, safety pharmacology, and other related testing to assess the safety and efficacy of new drugs and therapies.
- Manufacturing Support (Manufacturing): Provides testing and manufacturing support for biologics and cell therapies, including cell and gene therapy CDMO services, microbial solutions, and biologics testing.
Leadership and Structure
James C. Foster is the Chairman, President, and Chief Executive Officer. The company has a board of directors and is structured into the three core business segments mentioned above, each with its own leadership team.
Top Products and Market Share
Key Offerings
- Research Models: Specific Pathogen Free (SPF) rodents, genetically engineered models. Charles River is a major provider of research models globally. Competitors include Envigo (now part of Inotiv), Taconic Biosciences, and Janvier Labs. No exact market share revenue available.
- Preclinical Services: Toxicology, safety pharmacology, and discovery services to pharmaceutical and biotechnology companies. Charles River is a significant player in preclinical CRO market. Competitors include Labcorp Drug Development, Wuxi AppTec, and Eurofins Scientific. No exact market share revenue available.
- Cell and Gene Therapy CDMO: Contract development and manufacturing services for cell and gene therapies. Charles River is a growing player in this market. Competitors include Thermo Fisher Scientific, Catalent, and Lonza. No exact market share revenue available.
Market Dynamics
Industry Overview
The life sciences and drug development industry is experiencing strong growth driven by increasing R&D spending, technological advancements in drug discovery, and the growing demand for personalized medicine. Regulatory scrutiny and the complexity of drug development are also increasing the need for outsourced services.
Positioning
Charles River Laboratories is positioned as a leading end-to-end partner for drug discovery and development, offering a broad range of services from research models to manufacturing support. Its competitive advantages include its global reach, scientific expertise, and comprehensive service offerings.
Total Addressable Market (TAM)
The total addressable market for preclinical CROs and research model providers is estimated to be in the tens of billions of dollars. Charles River Laboratories, with its diverse portfolio, aims to capture a significant share of this market. No Specific TAM for cell and gene therapy CDMO.
Upturn SWOT Analysis
Strengths
- Global Presence
- Broad Service Portfolio
- Strong Reputation and Brand
- Scientific Expertise
- Long-Standing Customer Relationships
Weaknesses
- High Dependence on Pharmaceutical and Biotech R&D Spending
- Operational Risks in Animal Care
- Potential for Regulatory Scrutiny
- Integration Risks from Acquisitions
Opportunities
- Growing Demand for Cell and Gene Therapies
- Expansion in Emerging Markets
- Increasing Outsourcing of R&D Activities
- Advancements in Drug Discovery Technologies
- Further Acquisition Opportunities
Threats
- Economic Downturns Affecting R&D Budgets
- Increased Competition
- Changes in Regulatory Requirements
- Animal Rights Activism
- Supply Chain Disruptions
Competitors and Market Share
Key Competitors
- LH
- WUXI
- TMO
Competitive Landscape
Charles River Laboratories has a broad service portfolio, which is both an advantage and disadvantage compared to some specialized competitors. The company competes on scientific expertise, global reach, and service quality. They differentiate with their end-to-end service offerings compared to some competitors.
Major Acquisitions
Cognex Corporationu2019s Distributed Services and Products (DSP) business
- Year: 2024
- Acquisition Price (USD millions): 700
- Strategic Rationale: The acquisition is intended to build upon Charles River's existing Biologics Testing Solutions (BTS) business.
VCLS
- Year: 2023
- Acquisition Price (USD millions): 292
- Strategic Rationale: The acquisition is intended to expands Charles Riveru2019s integrated early-stage drug development portfolio by adding specialized translational biology services
Growth Trajectory and Initiatives
Historical Growth: Charles River Laboratories has experienced substantial growth through acquisitions and organic expansion. Its revenue has generally increased over the past decade, reflecting the growth in the pharmaceutical and biotechnology industries.
Future Projections: Future growth projections are based on analyst estimates, which indicate continued expansion driven by increased R&D spending and demand for outsourced services. Growth is expected in the CDMO sector.
Recent Initiatives: Recent strategic initiatives include acquisitions to expand capabilities in cell and gene therapy CDMO and investments in new technologies and infrastructure.
Summary
Charles River Laboratories is a strong player in the drug development space with a diversified portfolio and global presence. They are benefiting from the growth in R&D spending, but face competition and regulatory scrutiny. Acquisitions are key for growth, but integrations need to be watched. Financial performance is tied to the strength of the broader pharmaceutical and biotechnology industry.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Charles River Laboratories Investor Relations
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data is subject to change. This analysis is based on publicly available information and may not be fully comprehensive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Charles River Laboratories
Exchange NYSE | Headquaters Wilmington, MA, United States | ||
IPO Launch date 2000-06-23 | Chairman, President & CEO Mr. James C. Foster J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 18700 | Website https://www.criver.com |
Full time employees 18700 | Website https://www.criver.com | ||
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.